Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurotherapeutics
Asıl Yazarlar: Orefice, Nicola S., Alhouayek, Mireille, Carotenuto, Antonio, Montella, Silvana, Barbato, Franscesco, Comelli, Albert, Calignano, Antonio, Muccioli, Giulio G., Orefice, Giuseppe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824021/
https://ncbi.nlm.nih.gov/pubmed/26857391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-016-0420-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller